Received by email:

File: BRISIO News Release - IPA Investment - Sept 12 - FINAL.docx


/
 BRISIO INNOVATIONS INC.

FOR IMMEDIATE RELEASE CSE: BZI / OTC: NTCEF

Brisio Innovations Invests in ImmunoPrecise Antibodies Ltd. 

VANCOUVER, BRITISH COLUMBIA - (September 12, 2016) -- Brisio Innovations Inc. (CSE: BZI) (PINKSHEETS: NTCEF) (the "Com
--->pany") is pleased to announce that it has completed an investment in ImmunoPrecise Antibodies Ltd. ("IPA").

The Company has subscribed for a convertible note in the principal amount of $97,500 (the "Convertible Note").  In the
---> event that IPA completes a reverse takeover to list on stock exchange ("Pubco"), the principal amount of the Converti
--->ble Note will be convertible into 650,000 units of Pubco issued at a price of $0.15 per unit.

Each Unit will consist of one common share of Pubco (a "Pubco Share") and one share purchase warrant ("Pubco Warrant")
--->.  Each Pubco Warrant will entitle the Company to acquire one additional Pubco Share at a price of $0.30 per share for
---> a period of twelve (12) months from the date of issue of the Pubco Warrants.

IPA is a privately owned Canadian company located in Victoria, British Columbia, Canada. Their dedication to advancing
---> antibody development has resulted in cutting-edge immunological innovations.  IPA is comprised of experienced researc
--->h and development scientists and encompasses a wide range of distinctive competencies, including innovative technologi
--->es required in the production of monoclonal and polyclonal antibodies.  Their clients include leading companies in the
---> biotech and pharmaceutical sector, as well as government and academic researchers.

Paul Andreola, President of Brisio Innovations states, "We are quite excited with the opportunity to invest in a rapid
--->ly growing organization at this early stage. Management have proven themselves to be very skillful in their execution 
--->of their business strategy as evidenced by their high profile clients and high rate of growth. We look forward to thei
--->r continued performance and further success."

Brisio Innovations Inc.  Paul Andreola
President, CEO and Director (604) 644-0072  www.brisio.com,

 
About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (IPA) is a privately owned Canadian company located in Victoria, British Columbia, Canad
--->a. IPA's dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With ove
--->r 25 years of experience in the custom antibody business, IPA provides high customer satisfaction through a customized
---> professional approach.

IPA is comprised of experienced research and development scientists and encompasses a wide range of distinctive compet
--->encies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. IPA prid
--->es itself on its high customer satisfaction and its clients have grown accustomed to receiving very thorough and profe
--->ssional service. IPA customizes its client's projects to generate antibodies that meets their specific needs. IPA's cl
--->ients include: companies and scientists in the biotech and pharmaceutical sector, academic researchers and those emplo
--->yed by government.  For more information visit: http://www.immunoprecise.com/

About Brisio Innovations

Brisio Innovations Inc. invests its capital in companies and opportunities which management believes are undervalued a
--->nd have potential for significant appreciation. The company makes investments in both public and private markets and f
--->ocuses on opportunities in a wide variety of industries excluding the resource and resource service sectors. Brisio do
--->es not invest on behalf of any third party and it does not offer investment advice.


Disclaimer for Forward-Looking Information Certain statements in this news release are forward-looking statements, whi
--->ch reflect the expectations of management regarding potential future investments by the Company. Forward-looking state
--->ments consist of statements that are not purely historical, including any statements regarding beliefs, plans, expecta
--->tions or intentions regarding the future. Such statements are subject to risks and uncertainties that may cause actual
---> results, performance or developments to differ materially from those contained in the statements. No assurance can be
---> given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what bene
--->fits the Company will obtain from them. These forward-looking statements reflect management's current views and are ba
--->sed on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertai
--->nties could cause the Company's actual results to differ materially from those expressed or implied by the forward loo
--->king statements.